Search for: "U.S. v. Card*" Results 381 - 400 of 4,755
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Aug 2022, 1:35 pm by admin
The MDL trial court initially held that Singh’s proffered testimony was inadmissible because of his failure to consider daily dose.[3] In a second attempt, Singh offered an opinion for 10 mg daily dose of atorvastatin, based largely upon the results of a clinical trial known as ASCOT-LLA.[4] The ASCOT-LLA trial randomized 19,342 participants with hypertension and at least three other cardiovascular risk factors to two different anti-hypertensive medications. [read post]
24 Aug 2022, 5:01 am by Jim Dempsey
The privacy bill awaiting consideration in the U.S. [read post]
12 Aug 2022, 4:00 am by Jim Sedor
MSN – Kim Bellware (Washington Post) | Published: 8/9/2022 U.S. [read post]
10 Aug 2022, 9:05 pm by Eduardo Gallardo
(See Section 2.10(a)(ii)(E)(1) of form) Enhanced Informational Requirements It is standard practice for bylaws of U.S. publicly traded companies to require dissidents to give the corporation advance notice of their intent to make director nominations. [read post]